Browse EDEM2

Summary
SymbolEDEM2
NameER degradation enhancer, mannosidase alpha-like 2
Aliases FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum lumen
Domain PF01532 Glycosyl hydrolase family 47
Function

Initiates the endoplasmic reticulum-associated degradation (ERAD) that targets misfolded glycoproteins for degradation in an N-glycan-dependent manner. Catalyzes the first mannose trimming step, from Man9GlcNAc2 to Man8GlcNAc2 (PubMed:25092655). Extracts misfolded glycoproteins, but not glycoproteins undergoing productive folding, from the calnexin cycle.

> Gene Ontology
 
Biological Process GO:0006486 protein glycosylation
GO:0006487 protein N-linked glycosylation
GO:0006491 N-glycan processing
GO:0006516 glycoprotein catabolic process
GO:0006517 protein deglycosylation
GO:0006986 response to unfolded protein
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0009311 oligosaccharide metabolic process
GO:0009894 regulation of catabolic process
GO:0009896 positive regulation of catabolic process
GO:0010498 proteasomal protein catabolic process
GO:0030433 ER-associated ubiquitin-dependent protein catabolic process
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0030970 retrograde protein transport, ER to cytosol
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032527 protein exit from endoplasmic reticulum
GO:0033157 regulation of intracellular protein transport
GO:0034620 cellular response to unfolded protein
GO:0034976 response to endoplasmic reticulum stress
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0035977 protein deglycosylation involved in glycoprotein catabolic process
GO:0036503 ERAD pathway
GO:0036507 protein demannosylation
GO:0036508 protein alpha-1,2-demannosylation
GO:0036509 trimming of terminal mannose on B branch
GO:0042176 regulation of protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043413 macromolecule glycosylation
GO:0044723 single-organism carbohydrate metabolic process
GO:0045732 positive regulation of protein catabolic process
GO:0051222 positive regulation of protein transport
GO:0070085 glycosylation
GO:0070861 regulation of protein exit from endoplasmic reticulum
GO:0070863 positive regulation of protein exit from endoplasmic reticulum
GO:0090316 positive regulation of intracellular protein transport
GO:0097466 glycoprotein ERAD pathway
GO:1901136 carbohydrate derivative catabolic process
GO:1903513 endoplasmic reticulum to cytosol transport
GO:1903829 positive regulation of cellular protein localization
GO:1904152 regulation of retrograde protein transport, ER to cytosol
GO:1904154 positive regulation of retrograde protein transport, ER to cytosol
GO:1904292 regulation of ERAD pathway
GO:1904294 positive regulation of ERAD pathway
GO:1904380 endoplasmic reticulum mannose trimming
GO:1904382 mannose trimming involved in glycoprotein ERAD pathway
GO:1904587 response to glycoprotein
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0001948 glycoprotein binding
GO:0004553 hydrolase activity, hydrolyzing O-glycosyl compounds
GO:0004559 alpha-mannosidase activity
GO:0004571 mannosyl-oligosaccharide 1,2-alpha-mannosidase activity
GO:0015923 mannosidase activity
GO:0015924 mannosyl-oligosaccharide mannosidase activity
GO:0016798 hydrolase activity, acting on glycosyl bonds
Cellular Component GO:0005788 endoplasmic reticulum lumen
GO:0044322 endoplasmic reticulum quality control compartment
> KEGG and Reactome Pathway
 
KEGG hsa04141 Protein processing in endoplasmic reticulum
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-901042: Calnexin/calreticulin cycle
R-HSA-901032: ER Quality Control Compartment (ERQC)
R-HSA-392499: Metabolism of proteins
R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle
R-HSA-597592: Post-translational protein modification
Summary
SymbolEDEM2
NameER degradation enhancer, mannosidase alpha-like 2
Aliases FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EDEM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolEDEM2
NameER degradation enhancer, mannosidase alpha-like 2
Aliases FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EDEM2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 0.90; FDR: 0.047000 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolEDEM2
NameER degradation enhancer, mannosidase alpha-like 2
Aliases FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EDEM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1450.594
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0450.983
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2240.89
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1160.631
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1590.934
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0640.979
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0790.833
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0790.957
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0820.96
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1960.905
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0930.97
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0370.588
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EDEM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEDEM2
NameER degradation enhancer, mannosidase alpha-like 2
Aliases FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EDEM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEDEM2
NameER degradation enhancer, mannosidase alpha-like 2
Aliases FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EDEM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EDEM2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEDEM2
NameER degradation enhancer, mannosidase alpha-like 2
Aliases FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EDEM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEDEM2
NameER degradation enhancer, mannosidase alpha-like 2
Aliases FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EDEM2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEDEM2
NameER degradation enhancer, mannosidase alpha-like 2
Aliases FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EDEM2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEDEM2
NameER degradation enhancer, mannosidase alpha-like 2
Aliases FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ......
Chromosomal Location20q11.22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EDEM2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.